Evidence map›Paper›PMID 29844912›Full record

ArticleSAGE open medicine2018

Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004-2016.

Yumi Motooka, Toshinobu Matsui, Rachel M Slaton, Ryogo Umetsu, Akiho Fukuda, Misa Naganuma, Shiori Hasegawa, Sayaka Sasaoka, Haruna Hatahira, Kazuhiro Iguchi and 1 more

Open access · goldAbstract read
In one paragraph

Article in SAGE open medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Yumi MotookaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Toshinobu MatsuiLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Rachel M SlatonDepartment of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL, United States.
Ryogo UmetsuMicron Technology, Inc., Tokyo, Japan.
Akiho FukudaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Misa NaganumaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Shiori HasegawaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Sayaka SasaokaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Haruna HatahiraLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Kazuhiro IguchiLaboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Mitsuhiro NakamuraLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-5062-5522
Gifu Pharmaceutical University · JPMicron (Japan) · JPSamford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSeveral smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes are widely used. We evaluated the adverse events related to smoking cessation treatments and electronic cigarettes in the US Food and Drug Administration Adverse Event Reporting System database.

methodsWe analyzed reports of adverse events associated with smoking cessation treatment and electronic cigarettes terms dated between January 2004 and December 2016. We used the reporting odds ratio with 95% confidence intervals to detect a signal for each adverse event.

resultsIn total, 8,867,135 reports in the Food and Drug Administration Adverse Event Reporting System database were analyzed. The numbers of adverse events for nicotine replacement therapy (transdermal, buccal, oral, and respiratory administration) were 1673, 1016, 425, and 56, respectively. Nicotine replacement therapy (transdermal, buccal, and oral) demonstrated adverse events of nausea, nicotine dependence, and dizziness. For nicotine (transdermal) exposure, the top 5 adverse events reported were nausea (149 cases, reporting odds ratio: 2.28 (95% confidence interval: 1.92-2.69)), dizziness (132 cases, reporting odds ratio: 3.04 (95% confidence interval: 2.54-3.63)), application site erythema (108 cases, reporting odds ratio: 32.52 (95% confidence interval: 26.74-39.55)), headache (98 cases, reporting odds ratio: 1.84 (95% confidence interval: 1.50-2.25)), and dyspnea (94 cases, reporting odds ratio: 1.93 (95% confidence interval: 1.57-2.38)). Many cases of improper use of nicotine replacement therapies were reported. Nausea, depression, abnormal dreams, insomnia, and other adverse events were reported for varenicline. Insomnia, rash, anxiety, and dizziness were reported for bupropion. We observed electronic cigarettes-related adverse events such as dizziness, dyspnea, nausea, heart rate increased, and tremor.

conclusionOur findings suggest that an association exists between nicotine-related adverse events and nicotine replacement therapy. Healthcare professionals should closely monitor smokers trying to quit nicotine use for the misuse of nicotine replacement therapy. These findings may be informative to healthcare professionals in order to improve the management of smoking cessation treatment.

Indexed as

bupropionelectronic cigaretteFood and Drug Administration Adverse Event Reporting Systemnicotine replacement therapySmoking cessation treatmentvarenicline

Identifiers

PMID29844912
PMCPMC5966839
OpenAlexW2803378721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.